Loading…
Lobbying Spend
—
Filings
10
Firms Hired
1
Active Period
2023–2025
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Mikaela Naylon Give Kids a Chance Act
2025 · fourth_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S. 752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · fourth_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S. 752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1509
H.R. 1509/S. 752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 1637
Accelerating Kids’ Access to Care Act
2025 · fourth_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S. 752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 752
H.R. 1509/S. 752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · third_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · third_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1509
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 1637
Accelerating Kids’ Access to Care Act
2025 · third_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S.752
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · second_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Pediatric Review Voucher (PRV) reauthorization; Issues related to Medicaid value based payments; Issues related to cell and gene therapy; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · second_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Pediatric Review Voucher (PRV) reauthorization; Issues related to Medicaid value based payments; Issues related to cell and gene therapy; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1509
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Pediatric Review Voucher (PRV) reauthorization; Issues related to Medicaid value based payments; Issues related to cell and gene therapy; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 1637
Accelerating Kids’ Access to Care Act
2025 · second_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Pediatric Review Voucher (PRV) reauthorization; Issues related to Medicaid value based payments; Issues related to cell and gene therapy; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S.752
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; S. 1637, MVP Act of 2025; Pediatric Review Voucher (PRV) reauthorization; Issues related to Medicaid value based payments; Issues related to cell and gene therapy; Issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products
Client expense: — · Firm income: $50,000
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · first_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; The American Relief Act, 2025 (PL 118-158); Pediatric Review Voucher (PRV) reauthorization; S. 891, Bipartisan Health Care Act; Issues related to Medicaid value based payments; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · first_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; The American Relief Act, 2025 (PL 118-158); Pediatric Review Voucher (PRV) reauthorization; S. 891, Bipartisan Health Care Act; Issues related to Medicaid value based payments; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1509
Accelerating Kids’ Access to Care Act
2025 · first_quarter · Firm: AVENUE SOLUTIONS
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; The American Relief Act, 2025 (PL 118-158); Pediatric Review Voucher (PRV) reauthorization; S. 891, Bipartisan Health Care Act; Issues related to Medicaid value based payments; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model
Client expense: — · Firm income: $50,000
Matched citations: S.752
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; The American Relief Act, 2025 (PL 118-158); Pediatric Review Voucher (PRV) reauthorization; S. 891, Bipartisan Health Care Act; Issues related to Medicaid value based payments; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model
Client expense: — · Firm income: $50,000
Matched citations: S. 891
H.R. 1509/S.752, Accelerating Kids Access to Care Act; H.R. 1262/S. 932, Give Kids a Chance Act; The American Relief Act, 2025 (PL 118-158); Pediatric Review Voucher (PRV) reauthorization; S. 891, Bipartisan Health Care Act; Issues related to Medicaid value based payments; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model
Client expense: — · Firm income: $50,000
Matched citations: S. 932
H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10545
H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2666
Accelerating Kids’ Access to Care Act
2024 · fourth_quarter · Firm: AVENUE SOLUTIONS
H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4758
Creating Hope Reauthorization Act of 2024
2024 · fourth_quarter · Firm: AVENUE SOLUTIONS
H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7384
Accelerating Kids’ Access to Care Act
2024 · fourth_quarter · Firm: AVENUE SOLUTIONS
H.R. 2666/S. 4204, the Medicaid VBPs for Patients (MVP) Act; Center for Medicare and Medicaid Innovations (CMMI) Cell and Gene Therapy Access Model; H.R. 4758/S. 2372, Accelerating Kids Access to Care Act; H.R. 7384, Creating Hope Reauthorization Act of 2024; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: S. 2372
Source: Senate LDA